Caspase-8 (CASP8) is a cysteine protease that plays a central role in regulating cell death pathways, particularly extrinsic apoptosis initiated by death receptors. As an initiator caspase, caspase-8 sits at the apex of the caspase cascade, activated by death receptor engagement and then cleaving downstream executioner caspases to carry out programmed cell death[@kumar2019].
Beyond its well-established role in apoptosis, caspase-8 has emerged as a critical regulator of necroptosis, a form of programmed necrotic cell death, through its ability to cleave and inactivate RIPK1[@tummers2019]. This dual function as both a pro-apoptotic enzyme and a necroptosis inhibitor makes caspase-8 a crucial node in cell death decisions. In the context of neurodegeneration, caspase-8 dysregulation contributes to excessive neuronal death in Alzheimer's disease, Parkinson's disease, stroke, and traumatic brain injury, making it both a potential biomarker and therapeutic target[@neghta2021].
The protein is encoded by the CASP8 gene located on chromosome 2q33-34 in humans. Alternative splicing produces multiple isoforms, with the full-length caspase-8 (p55/p53) being the predominant form in most tissues. The zymogen exists as an inactive procaspase that requires proteolytic processing for activation.
| Attribute |
Value |
| Protein Name |
Caspase-8 |
| Gene Symbol |
CASP8 |
| UniProt ID |
Q14790 |
| Alternative Names |
MACH, FLICE, CAP4 |
| Molecular Weight |
~55 kDa (proenzyme), ~41 kDa (active subunits) |
| Protein Length |
479 amino acids |
| Chromosomal Location |
2q33.3 |
| Subcellular Location |
Cytoplasm, plasma membrane |
| Protein Family |
Caspase family, Initiator caspases |
¶ Structure and Activation
¶ Domain Architecture
Caspase-8 possesses a characteristic caspase structure:
N-Terminal Regions:
- DED1 (Death Effector Domain 1): N-terminal domain involved in protein-protein interactions with adaptor proteins like FADD
- DED2 (Death Effector Domain 2): Second DED, also participates in death receptor complex formation
- These DEDs allow caspase-8 to be recruited to the DISC (Death-Inducing Signaling Complex)
Catalytic Domain:
- Large subunit (p20): Contains the active site cysteine residue and substrate-binding pocket
- Small subunit (p10): Completes the catalytic site
- The proenzyme contains an interdomain linker that must be cleaved for activation
Caspase-8 is activated through two primary pathways[@tummers2019]:
1. Receptor-Mediated Activation (Extrinsic Pathway):
- Death ligands (FasL, TNF, TRAIL) bind their respective receptors
- Receptor oligomerization recruits adaptor proteins (FADD)
- Procaspase-8 is recruited to the DISC via DED-DED interactions
- High local concentration promotes autocatalytic cleavage
- Cleavage releases the active p18/p10 heterotetramer
2. Alternative Activation:
- Caspase-8 can be activated by caspase-3 (amplification loop)
- Can be activated by caspase-6 in some contexts
- Mitochondrial pathway can feed into caspase-8 activation
The primary function of caspase-8 is initiating extrinsic apoptosis[@kumar2019]:
- Death receptor engagement: Fas (CD95), TRAIL-R1/R2, TNF-R1
- DISC assembly: Recruitment of FADD and procaspase-8
- Pro caspase-8 activation: Autocatalytic cleavage at D175
- Executioner caspase activation: Cleavage of caspase-3 and -7
- Apoptotic execution: Proteolysis of cellular substrates
Caspase-8 critically regulates necroptosis through RIPK1 cleavage[@oberst2011][@hullbrand2020]:
- RIPK1 Phosphorylation: RIPK1 can be phosphorylated by RIPK3 in necroptosis
- Caspase-8 Cleavage: Active caspase-8 cleaves RIPK1 at D324
- Inhibition: Cleaved RIPK1 cannot form the necrosome
- Dual Role: Prevents both apoptosis and necroptosis depending on context
This regulatory function is essential for proper development and immune function, as mice lacking caspase-8 die embryonically due to uncontrolled necroptosis[@kaiser2011].
Caspase-8 also participates in other cell death modalities:
** pyroptosis**: Can activate in response to inflammasome signals
- Can cleave gasdermin D in some contexts
- Links extrinsic death pathways to inflammatory cell death
** Survival Functions**: Caspase-8 has non-apoptotic roles:
- NF-κB activation in some contexts
- Cell proliferation and differentiation signals
Caspase-8 contributes to AD pathogenesis through multiple mechanisms[@sanchez2022]:
Amyloid-beta-induced Apoptosis:
- Aβ oligomers activate caspase-8 in neurons
- Caspase-8 activation leads to downstream executioner caspase activation
- Neuronal apoptosis in affected brain regions
- Synaptic loss involves caspase-8-mediated mechanisms
Tau Pathology:
- Caspase-8 can cleave tau, generating truncated forms
- Caspase-8 activation correlates with tau pathology progression
- Truncated tau may be more aggregation-prone
Therapeutic Implications:
- Caspase-8 inhibitors show neuroprotective effects in AD models
- Must balance anti-apoptotic effects with potential necroptosis risks
In PD, caspase-8 participates in dopaminergic neuron death[@engler2022]:
Death Receptor Activation:
- Parkin mutations sensitize neurons to caspase-8 activation
- Environmental toxins activate caspase-8 pathway
- TNF-α levels elevated in PD brains promote caspase-8 activation
Mitochondrial Pathways:
- Cross-talk between intrinsic and extrinsic pathways
- Caspase-8 can amplify mitochondrial apoptosis signals
Neuroprotection Strategies:
- Caspase-8 inhibition protects dopaminergic neurons
- Death receptor blockade shows promise in models
¶ Stroke and Traumatic Brain Injury
Caspase-8 is a major contributor to secondary brain injury:
Ischemic Injury:
- Ischemia activates death receptor pathways
- Caspase-8 contributes to both apoptotic and necrotic cell death
- Inhibition reduces infarct size in animal models
Traumatic Brain Injury:
- Mechanical injury activates caspase-8
- Contributes to progressive neuronal loss
- Therapeutic window for intervention
Caspase-8 regulates inflammatory responses in the brain[@dumont2020]:
- Controls microglial activation states
- Affects cytokine production
- Links cell death to inflammation
- May have context-dependent pro-inflammatory effects
Several strategies for caspase-8 inhibition have been explored[@festjens2007][@zheng2023]:
| Strategy |
Compound |
Status |
Notes |
| Direct inhibitors |
Z-IETD-FMK |
Research use |
Not brain-penetrant |
| Peptide derivatives |
CASP8-targeted peptides |
Preclinical |
Limited stability |
| Allosteric inhibitors |
Various |
Discovery |
Novel mechanism |
| Gene therapy |
siRNA/shRNA |
Preclinical |
Delivery challenge |
- Necroptosis Risk: Complete inhibition may promote necroptosis
- Brain Penetration: Most inhibitors don't cross BBB
- Timing: Narrow therapeutic window for intervention
- Selectivity: Pan-caspase inhibitors cause toxicity
- Death receptor blockade: Targeting upstream activators
- RIPK1 inhibitors: Downstream of caspase-8
- Combination approaches: Multi-target strategies
| Property |
Value |
| Optimal pH |
7.2-7.6 |
| Substrate specificity |
IETD sequence (P1) |
| Km for substrates |
~10-50 μM |
| Turnover number |
~1-5 s⁻¹ |
| Inhibition |
Z-VAD-FMK (broad), Z-IETD-FMK (selective) |
- How can we achieve neuroprotective caspase-8 inhibition without promoting necroptosis?
- What are the cell-type-specific roles of caspase-8 in the brain?
- Can we develop brain-penetrant caspase-8 selective inhibitors?
- What is the timing window for therapeutic intervention?
- Targeted delivery: Nanoparticle-based inhibitor delivery
- Combination therapies: Multi-pathway targeting
- Biomarkers: Caspase-8 activity as biomarker
- Gene therapy: CRISPR-based approaches
- Kumar R, et al, Caspase-8 in apoptosis and beyond (2019)
- Tummers B, Green DR, Caspase-8: function, biology, and modulation (2019)
- Festjens N, et al, Caspase-8 as a therapeutic target (2007)
- Hublitz P, et al, Caspase-8 cleavage of RIPK1 regulates TNF-mediated apoptosis (2020)
- Kaiser WJ, et al, RIP3 mediates the embryonic lethality of caspase-8-deficient mice (2011)
- Oberst A, et al, Catalytic activity of caspase-8 on RIP1 (2011)
- Holler N, et al, Fas triggers an alternative, caspase-8-independent cell death pathway (2000)
- Neghta A, et al, Caspase-8 in neurodegeneration (2021)
- Sanchez A, et al, Caspase-8 and Alzheimer's disease (2022)
- Engler J, et al, Caspase-8 in Parkinson's disease models (2022)
- Vince JE, et al, Caspase-8 and RIPK1 interaction in TNF signaling (2018)
- Dumont K, et al, Caspase-8 and neuroinflammation (2020)
- Cullen SP, et al, Caspase-8 cleavage of caspase-3 (2011)
- Zheng M, et al, Targeting caspase-8 for neuroprotection (2023)